Affymax, Inc. (AFFY)

[spottrader]

In light of AFFY 15-1 endorsement...

While the Affymax drug would seem able to sail through the approval process with such an overwhelmingly positive vote, Becker’s report cites the case of Valeant Pharmaceuticals’ (VRX) drug Potiga. A secondary treatment for seizures in epilepsy patients, Potiga was endorsed 13-0 by an advisory panel in August of 2010 only to be rejected by the FDA four months later. The drug was ultimately approved by the FDA in June of last year.

Read more: http://www.minyanville.com/sectors/biotech-pharma/articles/map-pharmaceuticals-allergan-affymax-chelsea-therapeutics/3/9/2012/id/39823#ixzz1oer0nkx4


something to keep in mind...capitulation may take place. keep the powder dry risk takers!